Azithromycin Zentiva

Quick links

Choose a section

Quick links to important sections

Advertisements

Azithromycin Zentiva

Advertisements

Overview of Azithromycin Zentiva

Quick Facts

Property Description
Active Ingredient Azithromycin (as dihydrate)
Form & Status Film-coated tablet or oral suspension (Prescription Only)
Pharmacological Class Macrolide Antibiotic (Azalide Subclass)
Manufacturer Zentiva (Headquartered in Prague, Czech Republic)
Distinctive Feature Excellent tissue penetration and prolonged half-life

What is Azithromycin Zentiva?

Azithromycin Zentiva is a prescription-only medicine belonging to the macrolide class of antibiotics. It is utilized for the general treatment of susceptible bacterial infections across the body. It is a product of Zentiva, a pharmaceutical company based in the Czech Republic, and contains the universally recognized active ingredient, Azithromycin.

Pharmacological Class and Medical Recognition

The core substance, Azithromycin, is categorized as an azalide, a distinct subclass of macrolide antibiotics. This chemical structure is clinically recognized for providing enhanced stability and a wider range of activity compared to older macrolides. Pharmacological studies have consistently supported its utility in treating a variety of infections, earning it a place on the World Health Organization's (WHO) List of Essential Medicines. This global recognition confirms the drug's established safety and crucial role in medicine.

Composition, Form, and Unique Properties

Azithromycin Zentiva contains the active substance Azithromycin (typically as the dihydrate salt). While it is a generic version, its differentiating factor lies in Azithromycin’s ability to achieve high concentrations in tissues and white blood cells. This property is crucial for effective infection clearance at the site of infection. The product is supplied as an oral medicine—most commonly a film-coated tablet or a powder to be prepared as an oral suspension—for systemic administration.

Regulatory References

  1. Azithromycin - StatPearls (NIH)
Advertisements

What side effects are possible with Azithromycin Zentiva?

Adverse Reactions and Safety Information

Azithromycin is a macrolide antibiotic associated with a range of possible side effects, classified by regulatory agencies based on frequency and system-organ class.

Common Side Effects

The most frequently documented adverse reactions, classified as Common, primarily involve the gastrointestinal system. These include diarrhea, nausea, abdominal pain, and vomiting. These effects are typically mild and self-limiting.

Serious and Clinically Significant Risks

Several rare but serious adverse reactions have been documented in regulatory sources:

  • Cardiovascular Risks: Azithromycin may cause QT interval prolongation, increasing the risk of developing a potentially fatal irregular heart rhythm, known as Torsades de pointes. This risk is particularly noted in patients with pre-existing heart conditions or those taking other QT-prolonging medicines. A rare, increased short-term risk of acute cardiovascular death has been observed, particularly during the first five days of use.
  • Hepatotoxicity: Severe, and in some cases fatal, liver problems (hepatitis, hepatic necrosis, hepatic failure) have been reported. The drug is contraindicated in patients with a history of cholestatic jaundice or liver dysfunction associated with prior azithromycin use.
  • Hypersensitivity: Serious allergic reactions, including angioedema, anaphylaxis, and severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS syndrome, have occurred.
  • Other Risks: The drug may exacerbate symptoms of Myasthenia Gravis and is associated with the risk of Clostridioides difficile-Associated Diarrhea (CDAD). In neonates (up to 42 days old), reports of Infantile Hypertrophic Pyloric Stenosis (IHPS) are noted.

Safety Monitoring and Limitations

Use requires caution in patients with a known risk of arrhythmias, low potassium or magnesium levels, or significant hepatic or renal impairment. Due to the risk of ergotism, concomitant use with ergot derivatives is contraindicated. The long-lasting presence of the drug may contribute to the development of antimicrobial resistance.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory profile for Azithromycin overdosage focuses on the potential for severe cardiovascular events and the required immediate emergency response. Symptoms resulting from ingesting doses substantially higher than recommended are typically an intensification of common adverse reactions.

Documented Overdose Manifestations

Official labeling describes overdose presentations as primarily affecting the gastrointestinal system, including severe nausea, vomiting, and diarrhea. Beyond these symptoms, a critical regulatory focus is placed on the drug's effect on heart rhythm.

Severe Outcomes and Emergency Actions

Azithromycin overdose carries a risk for severe cardiovascular complications, notably prolongation of the QT interval and the development of Torsades de pointes, which is a potentially fatal irregular heart rhythm. The risk is elevated for patients with pre-existing heart conditions or low levels of potassium or magnesium.

Regulatory authorities mandate that if an irregular heartbeat, shortness of breath, dizziness, or fainting occurs, the individual must seek immediate medical attention.

Management and Antidote Status

In cases of overdosage, management involves the institution of general symptomatic and supportive measures. Official labeling confirms that no specific antidote is known for Azithromycin overdose. Patients may require observation for cardiac monitoring due to the risk of serious arrhythmias.

Advertisements

Therapeutic Uses of Azithromycin Zentiva

Azithromycin Zentiva is commonly used for conditions that cause disruptive symptoms across multiple therapeutic areas. This medication is relevant for managing symptoms related to specific bacterial infections, including upper and lower respiratory tract infections, skin and soft tissue conditions, and uncomplicated genital infections.

Addressing Acute Symptomatic Discomfort

This medication is generally used when patients experience sudden, intensified symptoms that interfere with daily functioning. It helps provide short-term symptomatic assistance to ease the overall burden of acute discomfort and temporary functional strain. In clinical settings, Azithromycin Zentiva is applied in contexts marked by increased discomfort where supportive management is appropriate.

“It helps improve day-to-day comfort during symptomatic periods, supporting the maintenance of functional stability.”

Supportive Management & Comfort

Azithromycin Zentiva supports the management of groups of symptoms that cluster into patterns or intensify over time. The medicine is also considered relevant in conditions characterized by episodic or fluctuating manifestations. It contributes to improved day-to-day comfort and supports a sense of stability when symptoms become more noticeable or momentarily overwhelming.


Quick Fact: Used for Conditions with Symptoms that Interfere with Daily Functioning


Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Azithromycin Zentiva

Official regulatory documents define strict criteria for Azithromycin Zentiva eligibility based on patient history, age, and pre-existing conditions.

Eligibility scope Official Regulatory Status
Populations for whom use is contraindicated Patients with a known history of hypersensitivity to Azithromycin or any macrolide/ketolide antibiotic, or a prior history of cholestatic jaundice/hepatic dysfunction associated with Azithromycin.
Populations for whom use is allowed Adults and older adults, provided no specific contraindications are present. Children who meet the minimum age/weight thresholds for the specific formulation.
Populations for whom use is not recommended Generally, children under 6 months of age (safety not established). Use is typically not recommended during pregnancy or lactation unless clearly needed.
Eligibility-related restrictions Caution is required for patients with pre-existing risk factors for QT interval prolongation (e.g., severe heart failure, uncorrected electrolyte issues), mild to moderate hepatic impairment, severe renal impairment (GFR < 10 mL/min), or Myasthenia Gravis.

Regulatory criteria establish absolute exclusions and restrictions for use. These mandatory checkpoints determine who is permitted, restricted, or prohibited from using the medicine based on physiological state and history.

Advertisements

What should I know about interactions with other medicines?

Azithromycin Zentiva Interactions with other medicines and products

Official regulatory documents establish mandatory constraints and monitoring requirements for Azithromycin Zentiva when co-administered with specific medicinal products. Co-administration with Ergot Derivatives (e.g., Ergotamine, Dihydroergotamine) is prohibited due to the theoretical risk of ergotism.


Pharmacodynamic and Transporter Interactions

Azithromycin may prolong the QT interval; therefore, concurrent use with other QT-prolonging drugs increases the risk of serious cardiac repolarization and Torsades de Pointes. The regulatory profile notes potential interaction with P-glycoprotein substrates, such as Digoxin and Colchicine, which can lead to increased serum concentrations of the co-administered drug. Separately, Azithromycin does not interact significantly with the hepatic cytochrome P450 system.


Exposure Modification and Administration Rules

Substances like Antacids (aluminum or magnesium-containing) can reduce Azithromycin's peak concentration (Cmax) through absorption inhibition, necessitating a mandatory 2-hour separation between doses. The antiretroviral Nelfinavir is documented to increase Azithromycin exposure. Concurrent use with Coumarin-type Oral Anticoagulants (e.g., Warfarin) has been associated with potentiated anticoagulant effects, requiring enhanced laboratory monitoring of prothrombin times. Furthermore, use requires caution in patients with significant hepatic disease due to the liver being the primary route of elimination, and the drug is contraindicated in severe hepatic impairment.

Advertisements

Mechanism of Action

Direct Inhibition of Bacterial Protein Synthesis

The action of Azithromycin involves a dual pharmacodynamic mechanism, initiated by the highly selective binding to the 23 S ribosomal rRNA of the bacterial mathbf50 S ribosomal subunit. This binding physically obstructs the nascent polypeptide exit tunnel , preventing the bacterial cell from completing its protein chains. This molecular interference halts the process of peptidyl translocation, consequentially resulting in a bacteriostatic effect. The physiological consequence at the cellular level is the halt of replication, limiting the pathogen's functional capability.

Modulation of Host Inflammatory Signaling

Azithromycin also engages mechanisms that regulate biological processes by acting on host immune cells. It interferes with key signaling pathways, contributing to the limitation of mediator activity, by targeting the activation of transcription factors such as the NF-kappa B cascade. The inhibition of this central transcription factor modifies the signaling output of targeted pathways by reducing the downstream release of pro-inflammatory cytokines. This results in the biochemical down-regulation of pro-inflammatory mediators, altering the local inflammatory response.

Advertisements

Dosage and Administration Information

How to Use Azithromycin Zentiva

Azithromycin Zentiva is administered based on standardized protocols detailed in official prescribing information, with the majority of use occurring via the oral route as tablets or suspension. The medicine is also approved for intravenous (IV) infusion to initiate treatment for severe infections in a clinical setting.


Official Dosing Regimens and Schedule

Use is structured around a once-daily frequency, reflecting the drug's prolonged presence in the body. Dosing typically follows one of a few fixed-duration patterns for acute infections, such as a 3-Day regimen (500 mg once daily) or a 5-Day regimen (500 mg on Day 1, then 250 mg on Days 2–5). A single oral dose of 1000 mg or 2000 mg is also prescribed for specific indications. For long-term prophylaxis of Mycobacterium avium complex (MAC), a distinct once-weekly schedule of 1200 mg is applied.


Administration Context and Special Conditions

Oral tablets and standard suspension generally may be taken with or without food; however, patients must strictly adhere to specific instructions for certain extended-release formulations, which often require an empty stomach. The IV formulation requires preparation via dilution and must be administered slowly as an infusion over at least 60 minutes, prohibiting rapid bolus or intramuscular injection. If a dose is missed, regulatory guidance advises taking the dose immediately and then returning to the established once-daily schedule. Pediatric dosing is determined by body weight (mg/kg), while no adjustment is typically necessary for older adults or those with mild to moderate kidney or liver impairment.

Advertisements

Recent Clinical Evidence

The Research Evidence Landscape

The research base for Azithromycin Zentiva includes many studies, primarily short-term Randomized Controlled Trials (RCTs) and Systematic Reviews. This research involves comparing the medicine against other established treatments or placebo to generate data, providing context for the drug's use in various infection research settings.

Evidence for Acute Infections

Research has explored the use of Azithromycin Zentiva for common infections, including Acute Respiratory Tract Infections (like pneumonia) and Uncomplicated Skin and Genital Infections. These studies used short treatment courses (often 3 to 5 days) and monitored patient-reported outcomes alongside bacteriological clearance of the target organisms. Studies report that patterns of symptom recovery and bacterial clearance measured during the study period were generally observed. Studies compared measurements of observed outcomes to those from groups using standard treatment options. The research focus is largely on uncomplicated presentations.

Long-Term Research and Study Gaps

Azithromycin has also been studied for its role in the long-term supportive management of specific chronic conditions, such as Cystic Fibrosis. These were Long-term RCTs, often lasting up to 12 months, which monitored lung function measurements and the frequency of acute disease flare-ups. While these trials reported documentation of changes in specific functional metrics, the magnitude of change suggests certainty remains low regarding sustained functional stability. A major documented limitation across the entire evidence base is the long-term risk of developing drug-resistant organisms, which is actively monitored by scientific bodies. Evidence is limited for complex, severe infections and for non-bacterial causes of respiratory symptoms.

Key Studies & References

  1. Azithromycin for the prevention of exacerbations in non-cystic fibrosis bronchiectasis: a randomised, double-blind, placebo-controlled trial (Meta-analysis context for long-term use)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Azithromycin Zentiva (FAQ)

Q: What are the known drug interactions to avoid while taking Azithromycin Zentiva?

Official regulatory documents indicate that co-administration with Ergot Derivatives is prohibited. Caution is generally advised when used concurrently with other QT-prolonging drugs due to the increased risk of a serious heart rhythm issue. Furthermore, official product information advises separating doses of Azithromycin Zentiva from certain Antacids and notes potential interactions with drugs like Warfarin and Digoxin.

Q: Does Azithromycin Zentiva interact with alcohol?

While Azithromycin is not generally known to interact directly with alcohol, official patient counseling often notes that patients are generally advised to discuss alcohol use with a healthcare professional. Alcohol consumption may potentially worsen common gastrointestinal side effects, such as nausea or vomiting, that are associated with the antibiotic.

Q: How is the intravenous form of Azithromycin Zentiva prepared before administration?

The intravenous (IV) formulation requires a preparation process involving reconstitution and further dilution. The initial powder is first reconstituted using a specific diluent to create a concentrated solution, which is then further diluted before it can be administered slowly as an infusion. Specific preparation details are outlined in the official prescribing information.

Q: Can Azithromycin Zentiva be crushed or split if I have trouble swallowing the tablet?

Regulatory documents describe the product as a film-coated tablet, which often implies that it should be swallowed whole. Official prescribing information generally advises that film-coated tablets should be swallowed whole, and the regulatory label does not typically provide instructions for modifying the tablet by crushing or splitting.

Q: What happens if I accidentally take two doses of Azithromycin Zentiva at once?

Official information on overdose states that symptoms typically resemble common adverse reactions, such as increased nausea, vomiting, and diarrhea. If this occurs, contact with a poison control center or seeking medical assistance should be considered immediately, as general symptomatic and supportive care is advised.

Q: What should I do if my child vomits shortly after taking the oral suspension?

If a child vomits within a specific short period after receiving the oral suspension, official patient information advises that contact with a healthcare provider is necessary. A second dose should generally not be given unless specifically instructed by a healthcare professional, who will determine if a repeat dose is needed.

Advertisements

How should Azithromycin Zentiva be stored and disposed of?

Storage and Disposal of Azithromycin Zentiva

Azithromycin Zentiva film-coated tablets do not require any special storage conditions regarding temperature, according to official regulatory information. The medicine should be kept in its original container, tightly closed, and stored away from excess heat and moisture.


Mandatory Storage and Disposal Rules

Area Regulatory Requirement
Child Safety Keep medicine out of the sight and reach of children.
Stability Do not use after the expiry date (EXP) stated on the packaging.
Disposal Do not throw away via wastewater or household waste.

All unused or expired product must be disposed of in accordance with local requirements, typically by returning it to a pharmacist or a designated pharmaceutical waste collection program. This process prevents the active antibiotic substance from entering the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azithromycin Zentiva found in:

A-Z Index: